SAN DIEGO, Nov. 28, 2021 /PRNewswire/ -- Novarad, a
leader in the development of medical imaging software, today
announced a partnership with CureMetrix, Inc., a pioneering
healthcare technology company that delivers artificial intelligence
(AI)-driven solutions for radiology. Novarad's imaging tools,
integrated with the CureMetrix AI-driven women's health suite of
tools for mammography, will be distributed nationally in the U.S.
Novarad will be the exclusive PACS distributor of CureMetrix
AI for small and midsized imaging centers and hospitals.
"Our vision for transformative imaging technology aligns
perfectly with the mission of CureMetrix to support and advance
women's health," said David
Grandpre, Senior Director of Product at Novarad. "By
integrating these highly trained, proven algorithms with our
existing mammography offerings, radiologists will be able to
streamline their workflow, reduce false positives and enhance their
ability to diagnose breast cancer earlier. That's why we are
excited to bring CureMetrix AI for mammography to Novarad customers
and help save more lives."
The potential impact of the CureMetrix AI innovations in
radiology have been featured in both the Journal of the American
College of Radiology (JACR) and in the Journal of Digital Imaging
(JDI). CureMetrix's FDA-cleared cmTriage® is an
application that prioritizes suspicious cases directly into the
radiology worklist. Mammography exams are then processed by
cmAssist®, a sophisticated AI-based CAD algorithm
intended to identify, mark and score suspicious lesions to support
the radiologist. And then cmDensity™ automatically classifies the
patient's breast density according to the standards set by the
American College of Radiology (ACR), BIRADS Fifth Edition.
Studies have shown some of the following benefits:
- Faster reading time – 30% reduction in reading time
reviewing mammograms with a 71% reduction in flags over non-AI
CAD
- Improved cancer detection – 27% increase in early cancer
detection without an increase in false-positive recalls
- Fewer unnecessary patient recalls – 69% reduction in
false positives vs. traditional CAD, leaving more time for accurate
diagnoses
- Increased consistency and report automation
In addition, Novarad will be collaborating with CureMetrix on
the implementation of novel cmAngio™,
AI-based software intended to use a woman's mammogram to
help doctors assess her risk of coronary heart disease (CHD), the
number one killer of women.
"By integrating our AI solutions with Novarad's we can help
radiologists diagnose breast cancer earlier and more accurately,
and help doctors identify women at risk for CHD," said Navid Alipour, Chief Executive Officer of
CureMetrix. "CureMetrix solutions will enhance the performance of
physicians using Novarad's outstanding platforms, improving both
clinical and financial outcomes both now and well into the
future."
About Novarad
Located in the heart of Utah's Silicon Slopes, medical technology firm
Novarad® provides industry-leading healthcare solutions that enable
hospitals, imaging centers, clinics and physicians to work both
smarter and faster. The company's 30+ years of success are founded
on several core principles: transformative technology, a
people-centered approach, and service delivery excellence. Visit
Novarad at http://www.novarad.net for more
information.
About CureMetrix
CureMetrix is a global leader in
Artificial Intelligence for medical imaging, committed to advancing
technology that improves disease detection and cancer survival
rates across the globe. Its mission is to help save lives and
support improved clinical and financial outcomes, delivering
technology that radiologists, healthcare systems, and patients can
rely on with confidence.
cmTriage® is FDA-cleared for commercial use in
the U.S. cmTriage® and
cmAssist® are ANVISA cleared in Brazil. cmAssist®, cmAngio™, and
cmDensity™ are in development and are not yet available for
commercial use in the U.S. For more information about CureMetrix AI
solutions for women's health, visit www.CureMetrix.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novarad-partners-with-curemetrix-to-advance-ai-driven-mammography-301432574.html
SOURCE Novarad Corporation